ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (TBIAS COVERAGE DISTRIBUTION
ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T
HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T
ESMO 2021: Novel Treatment Strategies in Advanced Urothelial Cancer
ESMO 2021 new treatments for advanced urothelial cancer targeted therapies for advanced urothelial cancer, antibody-drug conjugates for advanced urothelial cancer, , advanced urothelial cancer patients fit for cisplatin-based therapy
BIAS COVERAGE DISTRIBUTION